

Dear Lakehouse Investor,

December was a tough month as global equity market volatility spilled over into Australia once again, sending the Fund's benchmark to its lowest level since July 2016. Unlike many investors who are panicking, though, our opportunistic team held tight onto the Fund's existing positions, topped up some that we think are particularly compelling to patient investors, and opened a position in a new company between the end of December and the time of writing. We are playing offense right now and are very much looking forward to reporting season, which might shake loose additional opportunities.

Companies Held:	22
Cash Allocation:	14.7%
Top 5 Portfolio Holdings:	33.3%
Net Asset Value per Unit:	\$1.3065 (ex 0.8654 cent distribution)
Fund Net Asset Value:	\$153.8 million (ex \$1.0 million distribution)
Benchmark:	S&P/ASX Small Ordinaries Accumulation Index

Turning to performance, the Fund returned -6.2% net of fees and expenses in December compared to a -4.2% return for the benchmark. For the fiscal year, the Fund has returned a net -7.0% compared to -12.7% for the benchmark. Since inception in mid-November 2016, the Fund has returned a net 37.8% compared to 14.2% for the benchmark.

Performance over the past few months has not been fun, however, rain or shine, we do not judge ourselves on short-term performance and neither should investors who embrace our long-term, high-conviction strategy. To that end, while it is still early days in the grand scheme of our pursuing long-term outperformance, we're pleased with our progress towards that goal, particularly given that our style is out of favour at the moment and that we've run with a conservative cash position ranging around 11% to 16% over the past year.

The Fund's most significant contributor to performance during December was **Pro Medicus** (+7.8%), which followed up the late-November announcement of its meaty Partners Healthcare win with the announcement of an expanded agreement with a German government hospital network. The most significant detractor was **Afterpay Touch** (-14.0%), which drifted downwards on no material news.

The Fund's five largest holdings as of the end of December accounted for 33.3% of the portfolio and are named in order of the Fund's allocation: Afterpay Touch, Pro Medicus, **Altium**, **Bapcor** and **Xero**. Longtime investors should recognise each of these names as they've been Fund holdings for some time.

Zooming out, the Fund's largest sector allocations as of the end of the month were to information technology (67.9% of total capital), health care (10.9%), and consumer discretionary (5.3%),

which is quite different to the benchmark's largest allocations: materials (19.5%), consumer discretionary (14.8%), and real estate (12.0%).

We continue to embrace a differentiated approach with an emphasis on companies and industries known for capital-light, recurring-revenue-centric business models. To that end, and considering the soft state of the Australian and Chinese economies, we are even more comfortable than usual being significantly underweight the likes of materials, consumer discretionary, and real estate.

Company News

We feel obliged to comment on BWX, which was not the fund's most significant detractor during the month but still made a mess of itself. The company downgraded its profit estimates for fiscal 2019 by 27% only two months after its last trading update, which in itself was a downgrade, and the stock price nearly halved in response. It looks more and more as if previous management was dressing the business up for sale in part by aggressively pushing stock into domestic and international channels as well as acquiring three businesses in as many months to beef up sales and earnings. Notably, unlike most institutional holders, we declined to participate in the capital raises to fund those acquisitions.

Previous management's rush for growth has now backfired to some degree: there has been major destocking by Australian pharmacies, whilst new management (sensibly) decided to slow the pacing of the international rollout. BWX's company-wide ERP program implemented in July experienced growing pains, which temporarily made things worse, and its US business has been adrift amidst softening retail sales, further deepening the downgrade.

The faint silver lining to all this is that Sukin sales to consumers in Australia, the US and Canada remain healthy, and many of the factors in transition such as ERP, US hires, and new market strategies have been settled now. Even though we are quite disappointed by how things have unfolded and regret not trimming this position by more sooner, we think some of the company's current pain points, particularly the destocking and ERP headaches, are temporary and the Fund still retains a small position.

Interim Distribution & Looking Ahead

We're pleased to note the Fund has announced its half-year distribution for fiscal 2019 of \$0.0087 per unit, bringing the total distributions paid per unit since inception to \$0.0789. That said, we remind investors that our strategy is not income-centric and that our long-term, high-conviction approach will continue to make for lumpy distributions.

It is also worth remembering that the net asset value per unit of the Fund falls dollar for dollar with the size of the per-unit distributions to investors -- we're moving money from the Fund's

pocket to investors' pockets -- and so the net asset value per unit will increasingly understate the Fund's since-inception performance over time. The performance numbers included in these letters and the data on our website do account for distributions and their reinvestment, however, and so we encourage investors to use these as the source of truth on performance rather than eyeballing the net asset value per unit.

The next couple of months should be eventful as we move toward half-year reporting season in February. We look forward to receiving updates from our portfolio companies, sitting down with executive teams, exploring new opportunities and deploying more of the Fund's cash balance.

Thanks to all our investors for your time and trust. We're honoured to have you with us and look forward to what the future holds.

Best Regards,



Joe Magyer, CFA
Chief Investment Officer

Sole use and confidentiality: This report has been prepared by Lakehouse Capital Pty Limited (ABN 30 614 957 603, authorised representative of AFSL 400691) and by its officers, employees and agents (collectively "Lakehouse") for the sole use of its clients as a record of the performance of their investment. The contents of this report are confidential, and the client may only disclose such contents to its officers, employees or advisers on a need to know basis, or with the prior written consent of Lakehouse.

Disclaimer: The responsible entity for the Lakehouse Small Companies Fund (ARSN 615 265 864) is One Managed Investment Funds Limited (ACN 117 400 987) (AFSL 297042) ("OMIFL"). The information contained in this document was not prepared by OMIFL but prepared by other parties. All of the commentary, statements of opinion and recommendations contain only general advice and have not taken into account your personal circumstances. This report contains general financial product advice only. Any investment in Lakehouse or OMIFL products need to be made in accordance with and after reading the Product Disclosure Statement and Additional Product Disclosure Statement dated 15 November 2016. The opinions, advice, recommendations and other information contained in this report, whether express or implied, are published or made by Lakehouse in good faith in relation to the facts known at the time of preparation. Information is current as at the date of the letter, unless otherwise noted. Past performance is not indicative of future performance.

Limitation of liability: Whilst all care has been taken in preparation of this report, to the maximum extent permitted by law, neither Lakehouse or OMIFL will be liable in any way for any loss or damage suffered by you through use or reliance on this information. Lakehouse and OMIFL's liability for negligence, breach of contract or contravention of any law, which cannot be lawfully excluded, is limited, at Lakehouse's option and to the maximum extent permitted by law, to resupplying this information or any part of it to you, or to paying for the resupply of this information or any part of it to you.

Disclosure: Lakehouse, its directors, employees and affiliates, may, and likely do, hold units in the Lakehouse Small Companies Fund and securities in entities that are the subject of this report. Copyright: Lakehouse owns the copyright to this publication. Its contents may be used for your own personal use, but you must not (without Lakehouse's consent) alter, reproduce or distribute any part of this publication, transmit it to any other person or incorporate the information into any other document.